16 September 2026 editorial review · Trial
Verapamil to preserve residual insulin secretion in children: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT07199946; RECRUITING; updated 2025-09-30; enrollment 36 (ESTIMATED); results not posted.
Endpoint comparison: Change in C-peptide AUCmean 0-120 min) during an MMTT from baseline to month 24. (24 months); Number of participants with treatment-related adverse events as assessed by CTCAE v4.0". (24 months).
Sources for this record: NCT07199946: Verapamil to preserve residual insulin secretion in children (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.